[Improving the Efficiency and Safety of Human CCR5 Gene Editing by Selection of Optimal Guide RNAs for SpCAS9 and CAS12A].

Q3 Medicine
R R Mintaev, D V Glazkova, J A Taran, E V Bogoslovskaya, G A Shipulin
{"title":"[Improving the Efficiency and Safety of Human CCR5 Gene Editing by Selection of Optimal Guide RNAs for SpCAS9 and CAS12A].","authors":"R R Mintaev, D V Glazkova, J A Taran, E V Bogoslovskaya, G A Shipulin","doi":"10.31857/S0026898425020055, EDN: GGKOBN","DOIUrl":null,"url":null,"abstract":"<p><p>Advances in CRISPR/Cas-mediated genome editing have opened up treatment alternatives for many human diseases, including HIV infection. Knockout of the CCR5 gene as a potential way to treat HIV infection has long been studied. Here we analyzed guide RNAs for SpCas9 and AsCas12a nucleases targeting CCR5 gene which had been previously studied and selected the most effective among them. We also designed novel guide RNAs for the same nucleases using bioinformatics resources. We compared the efficiency of target site cleavage for all selected gRNAs using three nucleases: wt SpCas9, SpCas9-HF1-plus, and AsCas12a, as well as their off- target activities. We demonstrated that among the tested guide RNAs two for SpCas9- HF1-plus and three for AsCas12a exhibited high cleavage activity, cutting CCR5 gene in 60-72% of cells, and had off-target activities below the limit of detection. Thus, these guide RNAs may be candidates for future development of gene therapies against HIV infection.</p>","PeriodicalId":39818,"journal":{"name":"Molekulyarnaya Biologiya","volume":"59 2","pages":"234-243"},"PeriodicalIF":0.0000,"publicationDate":"2025-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Molekulyarnaya Biologiya","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.31857/S0026898425020055, EDN: GGKOBN","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q3","JCRName":"Medicine","Score":null,"Total":0}
引用次数: 0

Abstract

Advances in CRISPR/Cas-mediated genome editing have opened up treatment alternatives for many human diseases, including HIV infection. Knockout of the CCR5 gene as a potential way to treat HIV infection has long been studied. Here we analyzed guide RNAs for SpCas9 and AsCas12a nucleases targeting CCR5 gene which had been previously studied and selected the most effective among them. We also designed novel guide RNAs for the same nucleases using bioinformatics resources. We compared the efficiency of target site cleavage for all selected gRNAs using three nucleases: wt SpCas9, SpCas9-HF1-plus, and AsCas12a, as well as their off- target activities. We demonstrated that among the tested guide RNAs two for SpCas9- HF1-plus and three for AsCas12a exhibited high cleavage activity, cutting CCR5 gene in 60-72% of cells, and had off-target activities below the limit of detection. Thus, these guide RNAs may be candidates for future development of gene therapies against HIV infection.

[通过选择SpCAS9和CAS12A的最佳引导rna提高人类CCR5基因编辑的效率和安全性]。
CRISPR/ cas介导的基因组编辑技术的进展为包括艾滋病毒感染在内的许多人类疾病开辟了治疗方案。长期以来,人们一直在研究敲除CCR5基因作为治疗HIV感染的一种潜在方法。本文对已有研究的靶向CCR5基因的SpCas9和AsCas12a核酸酶的引导rna进行了分析,选择了其中最有效的。我们还利用生物信息学资源为相同的核酸酶设计了新的引导rna。我们比较了使用三种核酸酶(wt SpCas9、SpCas9- hf1 -plus和AsCas12a)对所有选定的grna的靶位点切割效率及其靶外活性。我们证明,在测试的两个SpCas9- HF1-plus向导rna和三个AsCas12a向导rna表现出高的切割活性,在60-72%的细胞中切割CCR5基因,并且具有低于检测极限的脱靶活性。因此,这些引导rna可能是未来开发抗HIV感染基因疗法的候选物。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
Molekulyarnaya Biologiya
Molekulyarnaya Biologiya Medicine-Medicine (all)
CiteScore
0.70
自引率
0.00%
发文量
131
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:604180095
Book学术官方微信